Featured Research

from universities, journals, and other organizations

Aspirin Or NSAIDs Won't Prevent Colorectal Cancer

Date:
March 20, 2007
Source:
Agency for Healthcare Research and Quality
Summary:
People who are at average risk for colorectal cancer, including those with a family history of the disease, should not take aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) to try to prevent the disease, according to a new recommendation from the U.S. Preventive Services Task Force.

People who are at average risk for colorectal cancer, including those with a family history of the disease, should not take aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) to try to prevent the disease, according to a new recommendation from the U.S. Preventive Services Task Force.

This is the first time the Task Force has made a recommendation related to taking medicines to prevent colorectal cancer. After reviewing the latest evidence on the topic, the Task Force found that the potential harms of taking more than 300 mg per day of aspirin or NSAIDs--which can include increased risks for stroke, intestinal bleeding or kidney failure--outweigh the potential benefits of colorectal cancer prevention.

Meanwhile, patients taking aspirin to prevent other conditions such as heart disease should continue to discuss the benefits with their clinicians, according to Task Force Chair Ned Calonge, M.D., who is also Chief Medical Officer and State Epidemiologist for the Colorado Department of Public Health and Information. The Task Force found good evidence that taking low doses of aspirin (usually less than 100 mg) can reduce risk for heart disease but does not reduce the rate of colorectal cancer. In 2002, the Task Force strongly recommended that clinicians discuss the use of aspirin as a preventive medication with adults who are at increased risk for heart disease and that those discussions should address the potential benefits and harms of aspirin therapy.

Colorectal cancer is the third most common type of cancer in men and women and is the second-leading cause of cancer-related deaths in the United States. About 56,000 Americans die from colorectal cancer and 150,000 new cases are diagnosed each year. Between 5 percent and 6 percent of people develop colorectal cancer in their lifetime, and the majority of those diagnosed are over the age of 50.

Twenty percent of individuals diagnosed with colorectal cancer have a first- or second-degree relative with the disease, and African Americans have the highest rate of colorectal cancer compared with other races.

In recent years, some progress has been made to detect and treat colorectal cancer earlier through screening and early removal of polyps. In 2002, the Task Force strongly recommended that clinicians screen men and women age 50 and older for colorectal cancer.

Task Force leaders stress the evidence on the merits of screening but urge caution on taking preventive medicine for colorectal cancer. “Individuals taking high doses of aspirin or NSAIDs to prevent colorectal cancer should be aware of the potential harms and discuss them with their clinician,” said Dr. Calonge.

The U.S. Preventive Services Task Force is an independent panel of experts in prevention and primary care. The Task Force conducts rigorous, impartial assessments of the scientific evidence for the effectiveness of a broad range of clinical preventive services, including screening, counseling and preventive medications. Its recommendations are considered the gold standard for clinical preventive services. AHRQ provides technical and administrative support, but the recommendations of the panel are its own.

The Task Force based its conclusions on a report from a research team led by David Moher, M.D., at AHRQ's Evidence-based Practice Center at the University of Ottawa in Canada.

The Task Force grades the strength of the evidence as “A” (strongly recommends), “B” (recommends), “C” (no recommendation for or against), “D” (recommends against) or “I” (insufficient evidence to recommend for or against screening). The Task Force recommends against the routine use of aspirin and NSAIDs to prevent colorectal cancer in individuals at average risk for the disease (a “D” recommendation). The recommendation is published in the Annals of Internal Medicine.


Story Source:

The above story is based on materials provided by Agency for Healthcare Research and Quality. Note: Materials may be edited for content and length.


Cite This Page:

Agency for Healthcare Research and Quality. "Aspirin Or NSAIDs Won't Prevent Colorectal Cancer." ScienceDaily. ScienceDaily, 20 March 2007. <www.sciencedaily.com/releases/2007/03/070320083852.htm>.
Agency for Healthcare Research and Quality. (2007, March 20). Aspirin Or NSAIDs Won't Prevent Colorectal Cancer. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2007/03/070320083852.htm
Agency for Healthcare Research and Quality. "Aspirin Or NSAIDs Won't Prevent Colorectal Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/03/070320083852.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins